U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07690540) titled 'DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER' on July 02.
Brief Summary: In recent years, the introduction of immune checkpoint inhibitors (ICI) in combination with chemotherapy has significantly changed the management of advanced and recurrent Endometrial Cancer (EC).
Despite these advances, responses to immunotherapy remain heterogeneous. Not all patients with mismatch repair-deficient (dMMR) tumors derive durable benefit, while a subset of mismatch repair-proficient (pMMR) tumors may respond. In addition, ICI treatment is associated with relevant costs and immune-related toxicities, highlighting the need for impro...